Recent Analyst Stock Rating News
Arcturus Therapeutics Stock Is Rising Wednesday: What's Going On?
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Tesaro Shares Lower On Receipt Of FDA Complete Response Letter
Why The Amgen/Regeneron Patent Saga Is Far From Over
Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target
Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.